Mirae Asset Global ETFs Holdings’s Nurix Therapeutics NRIX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.88M	Sell	77,460 -437	-0.6%	-$7.44K	﹤0.01%	1284
2026 Q1	$1.2M	Sell	77,897 -1,428	-2%	-$23.7K	﹤0.01%	1433
2025 Q4	$1.51M	Buy	79,325 +39,227	+98%	+$564K	﹤0.01%	1299
2025 Q3	$371K	Sell	40,098 -4,907	-11%	-$51K	﹤0.01%	2015
2025 Q2	$514K	Sell	45,005 -4,799	-10%	-$51.9K	﹤0.01%	1808
2025 Q1	$593K	Buy	49,804 +5,286	+12%	+$88.4K	﹤0.01%	1775
2024 Q4	$838K	Buy	44,518 +5,899	+15%	+$135K	﹤0.01%	1641
2024 Q3	$870K	Buy	38,619 +9,044	+31%	+$205K	﹤0.01%	1619
2024 Q2	$617K	Buy	+29,575	New	+$461K	﹤0.01%	1720

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mirae Asset Global ETFs Holdings's NRIX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Nurix Therapeutics (NRIX) stake by 0.56% in Q2 2026, selling an estimated $7.44K and leaving 77,460 shares worth $1.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1284.

Mirae Asset Global ETFs Holdings first reported a position in NRIX in Q2 2024 and has held it in 9 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Mirae Asset Global ETFs Holdings held 77,460 shares of Nurix Therapeutics worth $1.88M as of Q2 2026.
Mirae Asset Global ETFs Holdings sold 437 Nurix Therapeutics shares in Q2 2026, an estimated $7.44K.
Nurix Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1284 holding.
Mirae Asset Global ETFs Holdings first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 9 quarters since.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.